Abstract: Notably, (3-ethylphenyl)boronic acid substituted indole-2-carboxamide maintained excellent activities against the single HIV-1 mutants L100I (EC50 = 7.3 nM), K103N (EC50 = 9.2 nM), as well as the double mutant V106A/F227L (EC50 = 21.1 nM).
Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.
PMID: 34897227
2022
Journal of acquired immune deficiency syndromes (1999)
Result: The treatment-naive participant had K103N and K70R in RT and Q148H and G140S in IN genes.
Table: K103N/S
Table: K103N
Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine.
PMID: 34978890
2022
Antimicrobial agents and chemotherapy
Discussion: Since the 48-week analysis in ATLAS-2M, 1 participant with HIV-1 subtype B and the L74I polymorphism met CVF criteria; this individual had RT mutations K103N and Y181C but no INSTI RAMs at CVF.
Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand.
PMID: 35001501
2022
Journal of the International AIDS Society
Method: We excluded individuals with prior evidence of NNRTI-associated resistance mutations based on the IAS-USA HIV drug-resistance mutations list (2019) (V90I, A98G, L100I, K101E/H/P/Q/R/N, K103N/S, V106A/M/I, V108I, E138K/A/G/Q/R, V179D/F/L/T, Y181C/I/V, Y188L/C/H, G190A/S/E,H221Y, P225H, F227L/C/R,
Molecular characterisation of the pol gene of vertically transmitted HIV-1 strains in children with virological failure.
PMID: 35302390
2022
AIDS research and human retroviruses
Abstract: M184V/I, K103N/S and Y181C were the most commonly occurring mutations, seen in 76%, 51% and 36% children.
Abstract: At BL, K103N (5), E138A/G (4) and M184V (3) were the most common mutations.
Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in North-Western Tanzania.
PMID: 35107140
2022
The Journal of antimicrobial chemotherapy
Abstract: Common mutations in RT were M184V (75%), T215Y (41.1%), K103N (39.3%), M41L (32.1%), D67DN (30.3%), G190A (28.6%) and A98G (26.8%).
Table: K103N
Discussion: Some of the most common mutations in this study were M184V, K103N, Y181C and G190A, which occurred at similar frequencies to those reported in studies from other SSA and Tanzanian settings.
Management of a human immunodeficiency virus case with discordant antiviral drug resistance profiles in cerebrospinal fluid compared with plasma: a case report.
PMID: 35164871
2022
Journal of medical case reports
Conclusion: The HIV-1 pol gene genotypic resistance analysis showed development of the NRTI M184V mutation, and NNRTI K103N and E138EK mutations in plasma, respectively.
Conclusion: The nonpolymorphic NNRTI K103N mutation causes high-level resistance to efavirenz (EFV), and E138K mutation causes potential low-level cross-resistance to EFV, which was discontinued together with 3TC.
Could Long-Acting Cabotegravir-Rilpivirine Be the Future for All People Living with HIV? Response Based on Genotype Resistance Test from a Multicenter Italian Cohort.
PMID: 35207677
2022
Journal of personalized medicine
Abstract: We excluded patients with HBsAg positivity, evidence of non-nucleoside reverse transcriptase inhibitor (except K103N) and integrase inhibitor mutations, and with a detectable HIV-RNA (>50 copies/mL).
Method: Therefore, we considered eligible for treatment with long-acting CAB/RPV, PWH with an undetectable HIV-RNA (<50 copies/mL) for at least 12 months, who are HBsAg negative, and who do not have evidence of NNRTI (except K103N) or Integrase Strand Transfer Inhibitor (INSTI) mutations.
Comparing effectiveness of first-line antiretroviral therapy between peri-urban and rural clinics in KwaZulu-Natal, South Africa.
Abstract: DT started within 7 days of first specialist consultation in all patients and the same day in 84.1%; 3.4% had baseline resistance mutations (K103N, V106I + E138A, and V108I); 12.5% were lost to follow-up.
Result: Baseline resistance mutations (K103N, V106I + E138A, and V108I, respectively) were detected in three patients (3.4%).
HIV mutation literature information.
PMID: 
2022
Bioorganic & medicinal chemistry
Browser Board
Co-occurred Entities
Filtrator
ViMRT